贝达药业：目前MCLA-129的多项临床研究工作正有序推进中

Group 1 - The core viewpoint of the article is that Betta Pharmaceuticals is actively progressing with multiple clinical studies for MCLA-129 and will announce any significant developments in a timely manner [2] Group 2 - An investor inquired about the timeline for the removal of MCLA-129 from the pipeline and the calculation of losses associated with it [2] - Betta Pharmaceuticals responded that the clinical research for MCLA-129 is ongoing and organized [2]